QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by March, D. R. Articles by Fairlie, D. P. Search for Related Content PubMed PubMed Citation Articles by March, D. R. Articles by Fairlie, D. P.

Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity

Institute for Molecular Bioscience (D.R.M., M.J.S., R.S., G.A., R.C.R., J.D.A.T., D.P.F.) and School of Biomedical Sciences (L.M.P., T.M.W., K.W., N.P., S.M.T.), University of Queensland, Brisbane, Queensland, Australia

Human C5a is a plasma protein with potent chemoattractant and pro-inflammatory properties, and its overexpression correlates with severity of inflammatory diseases. C5a binds to its G protein-coupled receptor (C5aR) on polymorphonuclear leukocytes (PMNLs) through a high-affinity helical bundle and a low-affinity C terminus, the latter being solely responsible for receptor activation. Potent and selective C5a antagonists are predicted to be effective anti-inflammatory drugs, but no pharmacophore for small molecule antagonists has yet been developed, and it would significantly aid drug design. We have hypothesized that a turn conformation is important for activity of the C terminus of C5a and herein report small cyclic peptides that are stable turn mimics with potent antagonism at C5aR on human PMNLs. A comparison of solution structures for the C terminus of C5a, small acyclic peptide ligands, and cyclic antagonists supports the importance of a turn for receptor binding. Competition between a cyclic antagonist and either C5a or an acyclic agonist for C5aR on PMNLs supports a common or overlapping binding site on the C5aR. Structure-activity relationships for 60 cyclic analogs were evaluated by competitive radioligand binding with C5a (affinity) and myeloperoxidase release (antagonist potency) from human PMNLs, with 20 compounds having high antagonist potencies (IC₅₀, 20 nM-1 µM). Computer modeling comparisons reveal that potent antagonists share a common cyclic backbone shape, with affinity-determining side chains of defined volume projecting from the cyclic scaffold. These results define a new pharmacophore for C5a antagonist development and advance our understanding of ligand recognition and receptor activation of this G protein-coupled receptor.

Address correspondence to: Professor David Fairlie, Institute for Molecular Bioscience, University of Queensland, St Lucia QLD 4072, Australia. E-mail: d.fairlie{at}imb.uq.edu.au

This article has been cited by other articles:

				J. H. Ippel, C. J. C. de Haas, A. Bunschoten, J. A. G. van Strijp, J. A. W. Kruijtzer, R. M. J. Liskamp, and J. Kemmink Structure of the Tyrosine-sulfated C5a Receptor N Terminus in Complex with Chemotaxis Inhibitory Protein of Staphylococcus aureus J. Biol. Chem., May 1, 2009; 284(18): 12363 - 12372. [Abstract] [Full Text] [PDF]

				R. S. Griffin, M. Costigan, G. J. Brenner, C. Him Eddie Ma, J. Scholz, A. Moss, A. J. Allchorne, G. L. Stahl, and C. J. Woolf Complement Induction in Spinal Cord Microglia Results in Anaphylatoxin C5a-Mediated Pain Hypersensitivity J. Neurosci., August 8, 2007; 27(32): 8699 - 8708. [Abstract] [Full Text] [PDF]

				T. M. Woodruff, J. W. Crane, L. M. Proctor, K. M. Buller, A. B. Shek, K. de Vos, S. Pollitt, H. M. Williams, I. A. Shiels, P. N. Monk, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration FASEB J, July 1, 2006; 20(9): 1407 - 1417. [Abstract] [Full Text] [PDF]

				J. M. Mathiesen, A. Christopoulos, T. Ulven, J. F. Royer, M. Campillo, A. Heinemann, L. Pardo, and E. Kostenis On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2 Mol. Pharmacol., April 1, 2006; 69(4): 1441 - 1453. [Abstract] [Full Text] [PDF]

				T. M. Woodruff, S. Pollitt, L. M. Proctor, S. Z. Stocks, H. D. Manthey, H. M. Williams, I. B. Mahadevan, I. A. Shiels, and S. M. Taylor Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 811 - 817. [Abstract] [Full Text] [PDF]

				A. Higginbottom, S. A. Cain, T. M. Woodruff, L. M. Proctor, P. K. Madala, J. D. A. Tyndall, S. M. Taylor, D. P. Fairlie, and P. N. Monk Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site J. Biol. Chem., May 6, 2005; 280(18): 17831 - 17840. [Abstract] [Full Text] [PDF]